Moderna, Inc. — Director's Dealing 2023

Apr 28, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2023-04-26

Reporting Person: Bancel Stephane (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2023-04-26	Common Stock	M	40000	$.99	Acquired	5451946	Direct
2023-04-26	Common Stock	S	7600	$130.27	Disposed	5444346	Direct
2023-04-26	Common Stock	S	16898	$131.10	Disposed	5427448	Direct
2023-04-26	Common Stock	S	9002	$132.55	Disposed	5418446	Direct
2023-04-26	Common Stock	S	6500	$133.93	Disposed	5411946	Direct
2023-04-27	Common Stock	M	40000	$.99	Acquired	5451946	Direct
2023-04-27	Common Stock	S	29600	$130.41	Disposed	5422346	Direct
2023-04-27	Common Stock	S	9900	$131.16	Disposed	5412446	Direct
2023-04-27	Common Stock	S	500	$131.90	Disposed	5411946	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-04-26	Stock Option (Right to Buy)	$.99	M	40000	Disposed	2023-08-19	Common Stock (40000)	Direct
2023-04-27	Stock Option (Right to Buy)	$.99	M	40000	Disposed	2023-08-19	Common Stock (40000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	9050372	Indirect
Common Stock	6564880	Indirect

Footnotes

F1: These shares are owned directly by Boston Biotech Ventures, LLC ("Boston Biotech"). The reporting person is the majority equity unit holder and the sole managing member of Boston Biotech. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

F2: These shares are owned directly by OCHA LLC ("OCHA"). The reporting person is the majority equity unit holder and the sole managing member of OCHA. The reporting person disclaims Section 16 beneficial ownership of these securities, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for Section 16 or any other purpose.

F3: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on December 28, 2018, as last amended on March 15, 2022, and as further described in the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on May 24, 2022.

F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $129.90 to $130.89. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F5: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.91 to $131.84. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F6: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.99 to $132.83. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F7: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.63 to $134.27. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F8: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $129.87 to $130.87. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F9: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.88 to $131.87. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F10: This option is fully vested and exercisable.